Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an update.
Hansoh Pharmaceutical Group Company Limited announced that its self-developed B7-H3-targeted antibody-drug conjugate, HS-20093, has been granted Breakthrough-Therapy Designation by the National Medical Products Administration of China for treating osteosarcoma patients who have not responded to at least two prior therapies. This designation highlights the potential of HS-20093 in addressing unmet medical needs in osteosarcoma treatment, enhancing the company’s position in the oncology sector and potentially benefiting stakeholders through accelerated development and approval processes.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on developing innovative drugs. The company is involved in the research and development of treatments for various cancers and other serious health conditions.
YTD Price Performance: 9.95%
Average Trading Volume: 5,529,672
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$112.8B
For a thorough assessment of 3692 stock, go to TipRanks’ Stock Analysis page.